JP4472672B2 - 血漿の低温殺菌方法 - Google Patents
血漿の低温殺菌方法 Download PDFInfo
- Publication number
- JP4472672B2 JP4472672B2 JP2006211141A JP2006211141A JP4472672B2 JP 4472672 B2 JP4472672 B2 JP 4472672B2 JP 2006211141 A JP2006211141 A JP 2006211141A JP 2006211141 A JP2006211141 A JP 2006211141A JP 4472672 B2 JP4472672 B2 JP 4472672B2
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- composition
- pasteurization
- arginine
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- External Artificial Organs (AREA)
Description
― 800〜1,400g、好適には1,300gのソルビトール
― 400〜600g、好適には514gのサッカロース
― 3〜5mM、好適には4mMのグルコン酸カルシウム
― 8〜25mM、好適には15mMのクエン酸三ナトリウム
― 1〜10g、好適には5gのリジン
― 1〜10g、好適には5gのアルギニン。
上で定義した緩衝液に対して低温殺菌血漿の透析を行うことを含む、血漿の低温殺菌方法にも関する。
初期血漿1リットル当たりの量
ソルビトール 1,300g
サッカロース 514g
グルコン酸カルシウム 4mM
クエン酸三ナトリウム 15mM
リジン 5g
アルギニン 5g
― クエン酸三ナトリウム 10mM
― リジン 10g/L
― アルギニン 3g/L
― グルコン酸カルシウム 4mM
― 塩化ナトリウム 0.1M
0mosmol/Lの浸透圧および7から7.5のpHで透析を行う。
――――――――――――――――――――――――――――――――――――――
ウイルス ゲノム 構造 感染度の減少 期間
(log 10)
――――――――――――――――――――――――――――――――――――――
HIV RNA E >5 <10分間
ポリオサビン1 RNA NE >6.23 < 5時間
(POLIO SABIN 1)
ワクチン DNA E >4.30 < 1時間
ヘルペス−アウジェスキ DNA E >4.15 > 5時間
(HERPES-AUJESZKY)
パラインフルエンザ3型 RNA E >6.30 < 2時間
レオウイルス3型 RNA NE >3.28 ≦10時間
シンドビス(SINDBIS) RNA E >5.74 < 5時間
――――――――――――――――――――――――――――――――――――――
E=エンベロープ有り
NE=エンベロープ無し。
―――――――――――――――
濃 度 収 率
(U/ml) (%)
――――――――――――――――――――――――――――――――――――――
蛋白質(g/L) 60.0±106 93±2
第VIII因子:c(IU/mL) 1.10±0.26 94±7
第VIII因子:c(色素) 0.70±0.09 83±13
第V因子:c 1.12±0.25 83±4
第XI因子:c 0.98±0.06 88±7
第IX因子:c 0.64±0.10 59±7
第VII因子:c 0.65±0.05 67±6
フィブリノーゲンAg(g/L) 3.10±0.28 92±5
凝固性フィブリノーゲン(g/L) 2.50±0.17 92±3
抗トロンビンIII活性(g/L) 0.99±0.04 92±3
アルファ−1−抗トリプシン活性(g/L) 0.96±0.10 92±3
APTT 35−38秒 −
――――――――――――――――――――――――――――――――――――――
――――――――――――――――――――――――――――――――――――――
濃度(U/L)
―――――――――――――
トロンビン <0.01
PKA(%) <2
カリクレイン(%) 3
第IXa因子(U/mL) <0.1
第Xa因子(U/mL) <0.1
第VIIb/FVIIa因子 0.97
蛋白分解活性(S.2288−OD/mn) 0.03
フィブリノーゲン分解生成物(ng/mL) <250
――――――――――――――――――――――――――――――――――――――
――――――――――――――――――――――――――――――――――――――
ラットに対する試験:
− 血圧 <−2%
− 心拍 変化無し
− 毒性(静脈注射−25mL/kg) 毒性無し
ラビットに対する試験:
− 発熱性 発熱無し
――――――――――――――――――――――――――――――――――――――
Claims (1)
- 低温殺菌すべき初期血漿1リットル当たり以下の濃度の添加剤:
− 800〜1400gのソルビトール、
− 400〜600gのサッカロース、
− 3〜5mMのグルコン酸カルシウム、
− 8〜25mMのクエン酸三ナトリウム、
− 1〜10gのリジン、および
− 1〜10gのアルギニン
の混合物から構成されている、低温殺菌中の血漿を安定化するための組成物を血漿に添加することを含んでなり、該組成物を低温加熱殺菌段階の前に血漿に添加し、次いで、低温加熱殺菌段階の後、クエン酸三ナトリウム、グルコン酸カルシウム、塩化ナトリウム、リジンおよびアルギニンを含有する緩衝液に対して透析を行うことにより、該組成物から糖類を除去することを特徴とする血漿の低温殺菌方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9201604A FR2687317B1 (fr) | 1992-02-13 | 1992-02-13 | Composition pour stabiliser le plasma sanguin en cour de pasteurisation et solution plasmatique pasteurisee a usage therapeutique. |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP04609393A Division JP4010573B2 (ja) | 1992-02-13 | 1993-02-12 | 低温殺菌中の血漿を安定化するための組成物および治療学的用途のための低温殺菌血漿溶液 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006306892A JP2006306892A (ja) | 2006-11-09 |
JP4472672B2 true JP4472672B2 (ja) | 2010-06-02 |
Family
ID=9426597
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP04609393A Expired - Fee Related JP4010573B2 (ja) | 1992-02-13 | 1993-02-12 | 低温殺菌中の血漿を安定化するための組成物および治療学的用途のための低温殺菌血漿溶液 |
JP2006211141A Expired - Lifetime JP4472672B2 (ja) | 1992-02-13 | 2006-08-02 | 血漿の低温殺菌方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP04609393A Expired - Fee Related JP4010573B2 (ja) | 1992-02-13 | 1993-02-12 | 低温殺菌中の血漿を安定化するための組成物および治療学的用途のための低温殺菌血漿溶液 |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0556096B1 (ja) |
JP (2) | JP4010573B2 (ja) |
AT (1) | ATE171074T1 (ja) |
BR (1) | BR9300524A (ja) |
CA (1) | CA2089446C (ja) |
CZ (1) | CZ285573B6 (ja) |
DE (1) | DE69321007T2 (ja) |
DK (1) | DK0556096T3 (ja) |
EE (1) | EE03091B1 (ja) |
ES (1) | ES2121065T3 (ja) |
FI (1) | FI103380B1 (ja) |
FR (1) | FR2687317B1 (ja) |
HU (1) | HU210026B (ja) |
LT (1) | LT3226B (ja) |
LV (1) | LV10195B (ja) |
NO (1) | NO306532B1 (ja) |
PL (1) | PL174098B1 (ja) |
RU (1) | RU2112522C1 (ja) |
SK (1) | SK280665B6 (ja) |
UA (1) | UA27102C2 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9501189D0 (sv) * | 1995-03-31 | 1995-03-31 | Pharmacia Ab | Protein formulation |
US5616159A (en) * | 1995-04-14 | 1997-04-01 | Corning Incorporated | Method of forming high purity fused silica having high resistance to optical damage |
US6619073B2 (en) | 1996-03-05 | 2003-09-16 | Corning Incorporated | Method of increasing the initial transmittance of optical glass |
EP1018866B1 (en) * | 1996-06-14 | 2002-12-04 | Biostore New Zealand Limited | Compositions and methods for the preservation of living tissues |
US6361933B1 (en) | 1996-06-14 | 2002-03-26 | Biostore New Zealand Limited | Solutions for the preservation of tissues |
US5827640A (en) * | 1996-06-14 | 1998-10-27 | Biostore New Zealand Limited | Methods for the preservation of cells and tissues using trimethylamine oxide or betaine with raffinose or trehalose |
US6037116A (en) * | 1996-06-14 | 2000-03-14 | Biostore New Zealand, Ltd. | Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials |
US5962213A (en) * | 1996-06-14 | 1999-10-05 | Biostore New Zealand Limited | Compositions and methods for the preservation of living tissues |
US5879875A (en) * | 1996-06-14 | 1999-03-09 | Biostore New Zealand | Compositions and methods for the preservation of living tissues |
US6114107A (en) * | 1996-06-14 | 2000-09-05 | Biostore New Zealand Limited | Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues |
US6915665B2 (en) | 2000-10-31 | 2005-07-12 | Corning Incorporated | Method of inducing transmission in optical lithography preforms |
US20060019234A1 (en) * | 2004-07-22 | 2006-01-26 | Shanbrom Technologies, Llc | Modern blood banking employing improved cell preservation composition |
ES2264403B1 (es) * | 2006-06-22 | 2007-11-01 | Grifols S.A. | Medio de suspension de hematies. |
DE102011056142A1 (de) * | 2011-12-07 | 2013-06-13 | Manfred Rüdinger | Metabolisierbare Salze und deren Verwendung in Diagnostik und Therapie |
RU2639446C1 (ru) * | 2016-11-23 | 2017-12-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ хранения плазмы крови, содержащей лекарственные вещества с нестабильными фенольными гидроксилами |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3045153A1 (de) * | 1980-11-29 | 1982-07-08 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x |
DE3230849A1 (de) * | 1982-08-19 | 1984-02-23 | Behringwerke Ag, 3550 Marburg | Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung |
DE3237512A1 (de) * | 1982-10-09 | 1984-04-12 | Behringwerke Ag, 3550 Marburg | Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat |
US4470968A (en) * | 1983-01-13 | 1984-09-11 | Miles Laboratories, Inc. | Pasteurized therapeutically active blood coagulation factor concentrates |
JPS59134730A (ja) * | 1983-01-20 | 1984-08-02 | Green Cross Corp:The | 血液凝固第8因子の加熱処理法 |
DE3330770A1 (de) * | 1983-08-26 | 1985-03-14 | Behringwerke Ag, 3550 Marburg | Verfahren zur pasteurisierung von humanplasma |
FR2650508A1 (fr) * | 1989-08-01 | 1991-02-08 | Fondation Nale Transfusion San | Colle pasteurisee pour reunir des tissus humain ou animal |
FR2664165B1 (fr) | 1990-07-03 | 1992-10-16 | Lille Transfusion Sanguine | Composition pour stabiliser le plasma sanguin en cours de pasteurisation. |
-
1992
- 1992-02-13 FR FR9201604A patent/FR2687317B1/fr not_active Expired - Fee Related
-
1993
- 1993-02-04 ES ES93400279T patent/ES2121065T3/es not_active Expired - Lifetime
- 1993-02-04 EP EP93400279A patent/EP0556096B1/fr not_active Expired - Lifetime
- 1993-02-04 DK DK93400279T patent/DK0556096T3/da active
- 1993-02-04 AT AT93400279T patent/ATE171074T1/de not_active IP Right Cessation
- 1993-02-04 DE DE69321007T patent/DE69321007T2/de not_active Expired - Lifetime
- 1993-02-09 BR BR9300524A patent/BR9300524A/pt not_active Application Discontinuation
- 1993-02-09 CZ CZ93161A patent/CZ285573B6/cs not_active IP Right Cessation
- 1993-02-10 LV LVP-93-113A patent/LV10195B/en unknown
- 1993-02-10 SK SK82-93A patent/SK280665B6/sk not_active IP Right Cessation
- 1993-02-11 PL PL93297699A patent/PL174098B1/pl not_active IP Right Cessation
- 1993-02-11 NO NO930473A patent/NO306532B1/no not_active IP Right Cessation
- 1993-02-12 CA CA002089446A patent/CA2089446C/fr not_active Expired - Fee Related
- 1993-02-12 HU HU9300377A patent/HU210026B/hu not_active IP Right Cessation
- 1993-02-12 JP JP04609393A patent/JP4010573B2/ja not_active Expired - Fee Related
- 1993-02-12 LT LTIP338A patent/LT3226B/lt not_active IP Right Cessation
- 1993-02-12 FI FI930630A patent/FI103380B1/fi not_active IP Right Cessation
- 1993-06-15 UA UA93002940A patent/UA27102C2/uk unknown
-
1994
- 1994-05-23 EE EE9400005A patent/EE03091B1/xx not_active IP Right Cessation
-
1998
- 1998-02-12 RU RU93004727A patent/RU2112522C1/ru not_active IP Right Cessation
-
2006
- 2006-08-02 JP JP2006211141A patent/JP4472672B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4472672B2 (ja) | 血漿の低温殺菌方法 | |
EP0035204B1 (en) | Pasteurized therapeutically active protein compositions | |
US4623717A (en) | Pasteurized therapeutically active protein compositions | |
US4470968A (en) | Pasteurized therapeutically active blood coagulation factor concentrates | |
JP3133338B2 (ja) | ウイルス的に安全な生物学的組成物の調製方法 | |
AU549584B2 (en) | Heat stabilization of plasma proteins | |
EP0292003B1 (en) | Stabilzation of biological and pharmaceutical products during inactivation of viral and bacterial contaminants | |
JPS61189228A (ja) | 血液凝固第8因子製剤の製法 | |
FI96918B (fi) | Koostumus veriplasman stabiloimiseksi pastöroinnin aikana | |
JP2001000179A (ja) | ウィルスの不活化方法 | |
EP1057490A2 (en) | Use of tranexamic acid for the preparation of a human fibrinogen composition | |
JPS6140392B2 (ja) | ||
CA2228031A1 (en) | Doubly virus-inactivated human blood plasma, blood plasma derivatives produced therefrom and method for their production | |
JPH0530812B2 (ja) | ||
JPH09286798A (ja) | 活性蛋白質組成物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060802 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090728 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091028 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091102 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091127 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100128 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100223 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100303 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130312 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
EXPY | Cancellation because of completion of term |